Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers
- 5 November 2022
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (3) , 1312-1326
Abstract
The National Comprehensive Cancer Network recommends genetic testing in patients with potentially hereditary breast, ovarian, pancreatic, and prostate cancKeywords
This publication has 41 references indexed in Scilit:
- Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 MutationJournal of Clinical Oncology, 2014
- Quality of Cancer Family History and Referral for Genetic Counseling and Testing Among Oncology Practices: A Pilot Test of Quality Measures As Part of the American Society of Clinical Oncology Quality Oncology Practice InitiativeJournal of Clinical Oncology, 2014
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study GroupJournal of Clinical Oncology, 2012
- Underutilization of BRCA1/2 testing to guide breast cancer treatment: Black and Hispanic women particularly at riskGenetics in Medicine, 2011
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and MortalityJAMA, 2010
- Evaluating Women With Ovarian Cancer for BRCA1 and BRCA2 MutationsObstetrics & Gynecology, 2010
- Guidelines for Genetic Risk Assessment of Hereditary Breast and Ovarian Cancer: Early Disagreements and Low UtilizationJournal of General Internal Medicine, 2009
- The Impact of Acculturation on Awareness of Genetic Testing for Increased Cancer Risk among Hispanics in the Year 2000 National Health Interview SurveyCancer Epidemiology, Biomarkers & Prevention, 2006
- Racial Differences in the Use of BRCA1/2 Testing Among Women With a Family History of Breast or Ovarian CancerJAMA, 2005
- Interest in BRCA1/2 Testing in a Primary Care PopulationPreventive Medicine, 2002